导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.66% | 3661/4773 |
| 近一周 | -2.39% | 2049/5462 |
| 近一月 | -1.46% | 955/5421 |
| 近一季 | -0.88% | 903/5209 |
| 近半年 | -4.61% | 2558/4920 |
| 近一年 | -12.00% | 3533/4366 |
| 近两年 | 39.09% | 1937/2954 |
| 近三年 | 35.67% | 840/2253 |
| 成立以来 | 14.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.64% 4242/4961 |
-7.37% 3780/5312 |
- - |
- - |
| 2025 | 32.33% 1187/4813 |
16.67% 142/3635 |
3.35% 1037/4076 |
16.47% 2646/4524 |
-5.78% 3619/4813 |
| 2024 | 21.70% 405/3463 |
-2.69% 1411/2808 |
10.41% 37/3014 |
16.68% 1384/3129 |
-2.92% 2206/3463 |
| 2023 | -10.92% 1351/2656 |
1.23% 1612/2280 |
-0.77% 415/2385 |
-8.21% 1678/2515 |
-3.39% 678/2655 |
| 2022 | -6.04% 125/2207 |
-8.42% 281/1919 |
6.05% 778/2016 |
-15.79% 1344/2113 |
14.90% 77/2208 |
| 2021 | -15.10% 1155/1822 |
4.59% 145/1255 |
-0.01% 1120/1330 |
-13.52% 1346/1466 |
-6.13% 1533/1822 |
| 2020 | - - |
- - |
- - |
- - |
10.27% 603/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商上证港股通ETF VS. 长安沪深300非周期A(740101) |